Authors

• Klaus Lehmann‐Horn (ORCID: https://orcid.org/0000-0001-5488-7549)
• Ksenija Schirduan (ORCID: https://orcid.org/0009-0004-0666-7444)
• Clemens Gödel
• Boris-Alexander Kallmann
• Brigitte Wildemann
• Martin Marziniak (ORCID: https://orcid.org/0000-0003-2128-1246)
• Florian Then Bergh (ORCID: https://orcid.org/0000-0001-8604-8408)
• Markus C. Kowarik (ORCID: https://orcid.org/0000-0003-1389-5539)
• Veit Rothhammer
• Achim Berthele
• Sebastian Rauer (ORCID: https://orcid.org/0000-0002-9889-078X)
• Mathias Wahl

Institutions

• Heidelberg University (DE)
• University Medical Center Freiburg (DE)
• University Hospital Heidelberg (DE)
• Universitätsklinikum Erlangen (DE)
• Isar-Amper-Klinikum München-Ost (DE)
• Hertie Institute for Clinical Brain Research (DE)
• Orthopädische Praxis (DE)
• Technical University of Munich (DE)
• University of Tübingen (DE)
• Leipzig University (DE)
• University of Bamberg (DE)

Publication Details

Journal

Frontiers in Neurology

Published

2025-10-29

DOI

https://doi.org/10.3389/fneur.2025.1674742

Primary Topic

SARS-CoV-2 and COVID-19 Research

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Amgen
• Bristol-Myers Squibb
• Pfizer
• Sanofi
• Biogen
• Teva Pharmaceutical Industries
• Alexion Pharmaceuticals
• CSL Behring
• Argenx
• Deutsche Forschungsgemeinschaft
• Klaus Tschira Stiftung
• Neuraxpharm
• Bayer Vital
• Cilag